Advertisement


Clifford A. Hudis, MD, FASCO, FACP, on ASCO Guidelines Assistant

2025 ASCO Annual Meeting

Advertisement

Clifford A. Hudis, MD, FASCO, FACP, Chief Executive Officer of ASCO, discusses ASCO Guidelines Assistant, an AI-based collaboration between ASCO and Google Cloud which draws from ASCO’s evidence-based, published clinical practice guidelines, offering clinicians ready access to timely, trustworthy information.



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
I want to welcome everybody to the 2025 ASCO Annual Meeting. This is, as always, an exciting time in the year for us, when so much new science gets presented. Today, what I’m really excited about—above and beyond the cutting-edge new knowledge that’s being shared at this meeting—is how we’re going to distribute it to maximize impact for patients everywhere. The growth in information is something that we’re all grappling with. The explosion in publications—papers, that is—and information that could truly benefit patients is, I think, well known. The question is: how do we keep up? Even within ASCO, where we generate trusted, vetted, expert-prepared, peer-reviewed guidelines, it can be a problem just to find the information that a busy clinician needs in their day to make sure they are offering their patients the most up-to-date care possible. So thinking about those two related issues—the exploding basis of knowledge and the challenge of navigating to quick, accurate answers that a clinician can trust—the last year for us at ASCO has been an exciting one. We’ve partnered and collaborated with Google Cloud to create the ASCO Guidelines Assistant. And it is exactly what the name says—it’s really a discovery tool. What’s different about it compared to some other chat experiences that members may have had is that its answers to our questions are limited to the content of our guidelines. For every answer it gives, it automatically provides the relevant citation. If a user clicks on it, it shows them the specific guideline, when it was last updated, and it highlights in yellow the specific text within the guideline that supports the statement. So it addresses the question of trust, it addresses the question of discoverability, and it addresses the question of timeliness. We are really excited to be able to offer that to all of our members simply by logging on to the ASCO member app or going directly to the website at asco.org. GA—the name standing for Guidelines Assistant—is a small but really important step, I think, in our continuing journey to bring optimal, high-quality care to patients everywhere.

Related Videos

Lung Cancer

David Allen Barbie, MD, on Clinical and Molecular Features of Participants in the ADRIATIC Trial

David Allen Barbie, MD, of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, reviews specific clinical and molecular features of early progressors and long-term progression-free survivors from the phase III ADRIATIC trial, which assessed consolidation durvalumab vs placebo after concurrent chemoradiotherapy for limited-stage small cell lung cancer (Abstract 8014). 

Breast Cancer

Stephen K.L. Chia, MD, FRCPC, on Advanced HER2-Negative and ER-Positive Breast Cancer: SERD and AKT Inhibitor

Stephen K.L. Chia, MD, FRCPC, of BC Cancer Agency, reviews data from the phase III CCTG/BCT MA.40/FINER trial of fulvestrant and ipatasertib for advanced HER2-negative, ER-positive breast cancer following disease progression on first-line CDK 4/6 and aromatase inhibitors (LBA1005). 

Colorectal Cancer

Christopher M. Booth, MD, on a Structured Exercise Program for Patients With Colon Cancer

Christopher M. Booth, MD, of Queen’s University, reviews findings from the randomized phase III Canadian Cancer Trials Group (CCTG) CO.21 (CHALLENGE) trial, which evaluated the impact of a structured exercise program on disease-free survival in patients with stage III or high-risk stage II colon cancer (Abstract LBA3510). 

Colorectal Cancer

Heinz-Josef Lenz, MD, on MSI-H/dMMR Metastatic Colorectal Cancer: Expanded Analyses From CheckMate 8HW

Heinz-Josef Lenz, MD, of the University of Southern California Norris Comprehensive Cancer Center, reviews analyses from the CheckMate 8HW trial, which evaluated nivolumab plus ipilimumab vs chemotherapy or nivolumab monotherapy for microsatellite instability–high/mismatch repair–deficient (MSI-H/dMMR) metastatic colorectal cancer (Abstract 3501). 

Breast Cancer
Issues in Oncology

Neil M. Iyengar, MD, on Cancer Risk Reduction: Effects of Menopausal HRT and GLP-1 RAs

Neil M. Iyengar, MD, of Memorial Sloan Kettering Cancer Center, reviews several studies that aimed to answer two questions: does menopausal hormone therapy (HRT) impact overall survival and breast cancer–specific mortality in younger women diagnosed with high-risk disease (Abstract 10506); and do GLP-1 receptor agonists (GLP-1 RAs), a class of weight-loss medications, have cancer risk reduction properties (Abstracts 10507 and 10508). 

Advertisement

Advertisement




Advertisement